Skip to main content

Want a detailed portfolio tracker?

DCTH
NASDAQ
$12.59

Delcath Systems Inc (DCTH)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Website: https://www.delcath.com
68 analysts
Strong Buy
Target: $21.55 (+71.17%)

Market Cap

$454M

Forward P/E

25.77

P/E Ratio

880.89

Free Cash Flow Yield

4.23%

Price Chart

Valuation
Market Cap$454M
P/E880.89
Forward P/E25.77
PEG1.60
P/S5.03
P/B4.02
Profitability
Total Revenue (TTM)$90M
Gross Profit (TTM)$78M
EBITDA-$1.32M
Profit Margin-4.3%
Operating Margin-6.5%
EPS$0.02
Financial Health
Free Cash Flow Yield4.23%
Growth & Risk
Sharpe Ratio0.38